The dollar amounts are too small to change BrainsWay's core commercial trajectory. Monitor future quarters for evidence that these clinic partnerships actually drive incremental Deep TMS system placements and utilization, without that, this is just a passive financial investment. No material near-term catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $14.88entry
- T+1 · 6mo ago +0.07%α +0.72% · $14.89
- T+5 · 6mo ago +6.79%α +5.17% · $15.89
- T+20 · 5mo ago −5.04%α −6.62% · $14.13
- T+60 · 3mo ago +11.56%α +6.71% · $16.60
Price Chart
How similar events traded
Executive Summary
BrainsWay announced a strategic minority investment of $1.5M (with potential $1.5M in milestone-based investments) in Hopemark Health, a Chicago-area mental health clinic network. This is a small, structured equity deal that reinforces BrainsWay's strategy of deepening clinical partnerships for Deep TMS adoption, but the financial commitment is very modest relative to the company's enterprise value.
Key Financial Metrics
Key Facts
- BrainsWay invests $1.5M1.5 initially, up to $3.0M total including milestones, for a minority stake in Hopemark Health
- The investment takes the form of a preferred, annually compounding security with a redemption mechanism
- Hopemark operates multiple mental health clinics in the greater Chicago area, including ketamine-based therapies
- This continues BrainsWay's strategy of minority investments in growth-oriented clinical platforms to expand Deep TMS access
Financial Impact
$1.5M initial investment with another $1.5M in milestone tranches; total cap $3.0M, immaterial relative to BrainsWay's market cap
Risk Factors
- Investment size is tiny, fails to move the needle on revenue or earnings
- Minority stake with redemption mechanism provides no operational control; returns depend on Hopemark's execution
- Forward-looking statements about partnership benefits are non-binding marketing language
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296520 |
Track record
24 reports on BWAY
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers